期刊文献+

PTPRZ1在乳腺癌组织中的表达及临床意义 被引量:1

下载PDF
导出
摘要 【目的】探讨乳腺癌组织中PTPRZ1的表达及临床意义。[方法】选择2011年1月至2014年1月中南大学湘雅二医院乳腺甲状腺外科收治的120例女性患者。随机选取60例乳腺浸润性癌患者为观察组,60例同期乳腺纤维腺瘤患者为对照组。通过免疫组织化法,检测乳腺癌组织及乳腺纤维腺瘤组织中PTPRZ1的表达水平,比较PTPRZ1在乳腺癌患者的不同临床病理资料的表达水平。【结果】乳腺癌组织中PTPRZ1的表达水平显著高于乳腺纤维腺瘤组织,有统计学意义(P<0.05)。腋窝淋巴结是否转移、雌激素受体(ER)、孕激素受体(PR)是否阳性及不同类型的乳腺癌(三阴性和非三阴性)中PTPRZ1的表迭水平差异具有统计学意义(均P〈0.05),而年龄差异、绝经与否、肿瘤大小、Ki-67表达差异、Her-2是否阳性均与PTPRZ1表达水平差异均无统计学意义(均P〉0.05)。【结论】PTPRZ1的高表达可能与乳腺癌的发生、发展及预后不良相关。
出处 《医学临床研究》 CAS 2015年第9期1806-1808,共3页 Journal of Clinical Research
基金 国家自然科学基金(81441084)
  • 相关文献

参考文献10

  • 1Sun B,Zhang F, Wu SK, et al .Gene expression profiling forbreast cancer prognosis in Chinese populations[J]. Breast ,2011’ 17(2): 172-179.
  • 2郝文德,黄焰.血清学标志物在乳腺癌诊治中的临床研究进展[J].医学临床研究,2014,31(11):2276-2280. 被引量:4
  • 3Carey LAI,Dees EC,Sawyer L.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes[J].Clin Cancer Res,2007,13(8) : 2329-2334.
  • 4Makinoshima H, Ishii G,Kojima M. et al . PTPRZ1 regu-lates calmodulin phosphorylation and tumor progression insmall-cell lung carcinoma[J]. BMC Cancer, 2012 , 21 ( 12):537.
  • 5Deuel TF. Anaplastic lymphoma kinase: " Ligand Independ-ent Activation" mediated by the PTN/RPTP|3/^ signalingpathway[J]. Biochim Biophys Acta . 2013,1834(10) : 2219-2223.
  • 6tor protein tyrosine phosphatase beta with a monoclonal anti-body delays tumor growth in a glioblastoma model [ J ].Cancer Res * 2006, 66(44): 2271-2278.
  • 7Muller S,Kunkel P,Lamszus K,et al . A role for receptortyrosine phosphatase zeta in glioma cell migration [ J ].Oncogene , 2003, 22(43): 6661-6668.
  • 8Ulbricht U, Brockmann MA, Aigner A, et al . Expressionand function of the receptor protein tyrosine phosphatase zetaand its ligand pleiotrophin in human astrocytomas [ J]. JNeuropathol Exp Neurol * 2003, 62(12) : 1265-1275.
  • 9Ulbricht U, Eckerich C, Fillbrandt R,et al . RNA interfer-ence targeting protein tyrosine phosphatase zeta receptor-typeprotein tyrosine phosphatase beta suppress glioblastomagrowth in vitro and in vivo[J]. J Neurochem , 2006,98(5):1497-1506.
  • 10Alam NM, Roman MN, Samuel B, et al . Receptor-typetyrosine phosphatases ligands: looking for the needle in thehaystack[J].FEBS J , 2013, 280(2) : 388-400.

二级参考文献32

  • 1郑航,罗荣城.TPS、CA-153和CEA联合检测对乳腺癌的诊断价值[J].第一军医大学学报,2005,25(10):1293-1294. 被引量:46
  • 2盛世乐,黄钢.血清学标志物在乳腺癌诊治中的应用(文献综述)[J].放射免疫学杂志,2006,19(5):414-417. 被引量:2
  • 3Harada Y, Ohuchi N, Ishida T, e al. Tumor markers in breast cancer [J]. Can To Kagaku Ryoho ,2001,28(7) : 1035- 1040.
  • 4Saini S, Jagadish N, Gupta A, e al. A novel cancer testis antigen, A-kinase anchor protein 4 (AKAP4) is a potential biomarker for breast caneer[J]. PLoS One, 2013, 8 (2), e57095.
  • 5Kim BK, Lee JW, Park PJ, et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer[J]. Breast Cancer Res, 2009,11(2) : R22.
  • 6Hurt EM, Chan K, Serrat MA, et al. Identification of vitronectin as an extrinsic inducer of cancer stem cell differen- tiation and tumor formation[J]. Stem Cells, 2010,31 28 (3) : 390-398.
  • 7Kadowaki M, Sangai T, Nagashima T, et al . Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach[J]. J Cancer Res Clin Oncol , 2011,137(7) :1105-1115.
  • 8Watson MA,Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer[J]. Cancer Res, 1996,56(4) :860-865.
  • 9Reinholz MM, Nibbe A, Jonart LM, et al. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer[J]. Clin Cancer Res, 2005,11(10) : 3722-3732.
  • 10O'Brien N,O'Donovan N,Foley D, et al . Use of a panel of no- vel genes for differentiating breast cancer from non-breast tis- sues[J]. Tumour Biol, 2007,28(6) : 312-317.

共引文献3

同被引文献15

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部